Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (45)	5/6/2002 9:22:24 AM
From: tuck	Respond to of 566

>>SOUTH SAN FRANCISCO , Calif. -(Dow Jones)- Rigel Pharmaceuticals Inc. (RIGL) delivered six additional respiratory drug targets to Pfizer Inc. (PFE), thereby completing its discovery phase research collaboration. In a press release Monday, Rigel said it will receive an undisclosed amount of milestone payments for these targets that now may begin the next phase of preclinical research and development at Pfizer. The two companies originally signed an agreement in January 1999 to use Rigel's peptide libraries to identify intracellular drug targets that control the production of IgE, a key mediator in allergic reactions and asthma in B cells. Shares of Rigel closed Friday at $4.55, down 28 cents, or 5.8%, in Nasdaq trading.<< Cheers, Tuck